Amycretin
Amycretin is the former name of zenagamtide. Both names point to one drug in development. A Novo-funded trial measured a 24.3% mean weight reduction in its highest-dose group. The placebo change was 1.1% at week 36 (PMID 40550231; claims checked 24 August 2026). The EU field remains unclear.
What is Amycretin now called?
PMID 42532080 calls it “zenagamtide (formerly amycretin)” (claim checked 24 August 2026). The paper says one molecule acts at three receptor groups. Those groups are GLP-1, amylin, and calcitonin. Novo Nordisk funded the study. The old and new names can lead to the same trial. That is why both names stay on this page. The IDs let a reader check that the source means this drug. The link also keeps the old search name useful.
What did the human trial measure?
The randomised study included 125 adults. It assigned 101 to the study drug and 24 to placebo (PMID 40550231; claims checked 24 August 2026).
| Comparison | Estimated mean bodyweight change | Time | Funder |
|---|---|---|---|
| Highest-dose amycretin group | -24.3% | 36 weeks | Novo Nordisk |
| Placebo | -1.1% | 36 weeks | Novo Nordisk |
The same paper recorded what else happened in the trial.
| Trial finding | What PMID 40550231 reports |
|---|---|
| Most common new events | Gastrointestinal events |
| Severity and course | Most were mild or moderate and resolved by study end |
| Withdrawals | Many participants withdrew; a high share stopped for reasons unrelated to new adverse events |
These findings were checked on 24 August 2026. They stay beside the measured weight result.
What does evidence tier B mean here?
Randomised human trials now exist. The internal register assigns tier B (field checked 15 August 2026). A trial result does not set EU marketing status.
What is the recorded EU status?
The EU field remains unclear (field checked 15 August 2026). The sources show active drug trials. They do not show an EU marketing authorisation.
When was Amycretin first recorded?
The sources on this page give no first-observed month (checked 24 August 2026). The field stays empty instead of using a guess.
What other names and codes identify Amycretin?
The current name is zenagamtide. ClinicalTrials.gov record NCT06049329 uses code NNC0487-0111 for Amycretin (claim checked 24 August 2026).
Which identifiers belong to zenagamtide?
US FDA/NCATS GSRS lists zenagamtide as a protein. It gives the record these IDs:
| Identifier | Value |
|---|---|
| UNII | T2EA5S9XJ5 |
| CAS | 3005889-81-3 |
The GSRS record was checked on 24 August 2026.
What does this register entry cover?
This entry keeps identity, trial evidence, EU status, and vial evidence apart. It has no test result for a specific vial. A vial can only be assessed from evidence about that vial.